| | | | |

MICAH ROSENBLOOM Micah is the CEO and Chairman of Novophage. Prior to Novophage, Micah co-founded Brontes Technologies, Inc. in 2003 and served as General Manager of the business after its acquisition by 3M Corp in 2006. Brontes' technology was a breakthrough, handheld 3D imaging system that replaced traditional paste-based impressions. Prior to Brontes, Micah co-founded SimplyDone Business Solutions/ Handshake.com, in which he raised over $20,000,000 in financing from venture and strategic investors. Micah received his B.S. degree from Cornell University and his MBA from Harvard Business School. Micah is also on the Board of Advisors for Cornell's Entrepreneurship Program (E@C), and is a Founder Partner to the Founder Collective, a Boston/NYC based seed stage venture fund. MICHAEL KOERIS Mike is the President and COO of Novophage. He also remains a visiting scholar with the Howard Hughes Medical Institute in the Biomedical Engineering Department at Boston University and the Synthetic Biology Group at MIT. Mike did his doctoral work on network approaches to combat antibiotic-tolerant bacteria with Professor James Collins, and co- developed Novophage's technology, working with Dr Tim Lu. Prior to his doctoral degree, Mike graduated with a M.S. in Biochemistry from the Free University of Berlin, and was a recipient of the German Academic Exchange Fellowship (DAAD) to study at MIT. In addition to his scientific work, Mike previously worked at KPMG Consulting and McKinsey & Company in Germany, as well as Flagship Ventures in Cambridge. BRETT CHEVALIER Brett is the Chief Scientific Officer of Novophage. His expertise spans multiple biotechnology disciplines including systems and synthetic biology and genomics. Dr. Chevalier completed his Post-Doc at MIT and was a senior scientist at Agilent Technologies’ systems biology group (Cambridge, MA) and a New Venture Associate at Flagship Ventures. Dr. Chevalier has published over 15 peer-reviewed articles and 10 patents ranging from cancer therapeutics, stem cells, protein engineering, and microbiological applications. PROFESSOR TIMOTHY LU Tim is the Scientific Founder and Director of Novophage. Tim is also an assistant professor at MIT in the Synthetic Biology group as well as an associate fellow at the Broad Institute. He was selected as one of 35 young innovators under 35 by MIT's Technology Review, as well as awarded the 2008 Lemelson-MIT Student Prize and the 2008 National Inventors Hall of Fame Collegiate Inventors Competition Grand Prize for his work on engineered bacteriophage for the treatment of intractable bacterial infections. Tim graduated from MIT with an SB and an M.Eng. in Electrical Engineering and Computer Science and with a PhD from the Harvard-MIT Health Sciences and Technology Program in Electrical and Biomedical Engineering while receiving his doctoral training under Jim Collins at BU. SCIENTIFIC ADVISORY BOARD JIM COLLINS, PH.D.is the Chairman of Novophage's Scientific Advisory Board and Scientific Co-Founder of the company. He is an Investigator with the Howard Hughes Medical Institute, a University Professor at BU, and a Founding Professor at the Wyss Institute for Biological Inspired Engineering at Harvard University. Jim helped kick start what is now the emerging field of synthetic biology, and he is a pioneering researcher in systems biology. He has been recognized with numerous awards, starting with a Rhodes scholarship for his graduate work, and including both a McArthur "Genius" grant, as well as a NIH Director's Pioneer Award. Most recently Jim was awarded the Lagrange Prize from the CRT Foundation in Italy for his outstanding contributions relevant to the progress of complexity science. CHARLES COONEY, PH.D.is the Robert T Haslam (1911) Professor of Chemical Engineering and Faculty Director of the Deshpande Center for Technological Innovation at MIT. He has served as a consultant to multiple biotech and pharmaceutical companies, sits on the boards of Polypore International, and Biocon, Ltd. (India). He is a worldwide thought leader in biochemical engineering and pharmaceutical manufacturing, and his research and teaching interests span a range of topics in process engineering. He has published over 250 research papers, over 25 patents and co-authored/edited 5 books ROBERTO KOLTER, PH.D.is a Professor of Microbiology at Harvard Medical School, as well as the former president of the American Society for Microbiology (2009-2010). Roberto is one of the foremost scholars in the field of biofilms, their ecology and their impacts on industrial systems as well as patients. His research focuses on the study of biofilm communities and the ways in which interspecies interactions influence microbial community development. Roberto received his doctoral degree from UCSD and trained at Stanford as a postdoctoral scholar before becoming a Professor at Harvard. PHILIP STEWART, PH.D.is the Director of the Center for Biofilm Engineering at Montana State University, the worlds leading center for comprehensive biofilm research. Phil's research focuses on controlling and removing microbial biofilms, specifically by understanding the mechanisms that protect microbes in biofilms. These protective effects are based on the structure of the biofilm and include poor penetration of antimicrobial agents, phenotypic variation, and the activation of stress response pathways within the bacteria harbored in the biofilm. Phil was a NATO postdoctoral fellow at the Institut Jacques Monod in Paris, France and a senior chemical engineer at Bechtel Environmental in San Francisco, California, before joining the faculty at Montana State.